All Episodes
The Bio Report — 630 episodes
Innovating ADCs with Dual Targeting and Smarter Delivery
Targeting the Brain’s Immune System in Alzheimer’s Disease
How Gilead Is Building Durable Oncology and Immunology Franchises
Protecting the Brain After Stroke
Turning the Thymus into an Engine of Immune Tolerance in T1D and Beyond
Unlocking Major Targets with Mini Proteins
Addressing a Data Problem to Enable AI-Drug Discovery
Turning Multi Specific Antibody Design into an Engineering Discipline with AI
Addressing the Treatment Gap in Ischemic Stroke
A Pipeline in a Product that Reimagines Control of Inflammation
Building a Genetics Engine to Crack the Target Bottleneck
Stopping Shape-Shifting Tumors with a First-in-Class Epigenetic Drug
Rewriting the Rules of Antibody Drug Design
Mapping Cellular Stress Biology to Tackle Undruggable Targets
Turning Abandoned Drugs into Breakthroughs
Targeting Cancer Survival Genes in Solid Tumors
Addressing Treatment Gaps in Gout
An Off-the-Shelf Cell Therapy to Calm Cytokine Storms
Slowing Disability in MS
Tuning, Rather than Blocking, Immunity in IBD
Intercepting Cancer When DNA Surveillance Fails
Targeting Psychosis in Alzheimer’s Disease
A Class Action Suits Moves RICO from Mobsters to Medicine
Outsmarting Resistance with Rhythm
Editing Away Autoimmunity at the HLA Source
Why Asia is the Emerging Epicenter for Global Biopharmaceutical Progress
Reprogramming Cancer from Within
A Strategic Turn from Obesity to Cancer
A One Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer
Reprogramming T Cells to Cross the Brain’s Border
A Billion-Dollar Bet on AI-First Drug Development
Finding New Targets on the Surface of Misfolded Proteins
Targeting Tumors from the Inside Out
An Effort to Detect and Treat Alzheimer’s at Its Earliest Stages
The Year in Biotech and What’s Ahead for 2026
Developing an Alternative to Opioids for Post-Surgical Pain
Leveraging the Power of Vocal Biomarkers
Determining the Cause and Severity of Sepsis with a Point-of-Care Test
Separating Signal from Noise in Regenerative Therapies
Rewriting Drug Discovery with an AI-Multi-Omics Approach
Overcoming Chemoresistance and Activating the Immune System in Difficult-to-Treat Cancers
A Hub-and-Spoke Ophthalmology Company with an Eye for Innovation
An AI Collaborative that Welcomes All into the Fold
Hitting the Reset Button on Cellular Aging
Changing the Ovarian Cancer Treatment Landscape with a DNA-Mediated Immunotherapy
Why the United States Must Fall in Love with Biotechnology, or Take a Back Seat to China
Transforming Drug Discovery and Disease Research—One Cell at a Time
Scratching the Surface with a Novel Approach to Treating an Orphan Lung Disease
A Dual Action Approach to Treating MASH
Extending the Life of Transplanted Kidneys
Overcoming Antimicrobial Resistance
Using Targeted Radiotherapies to Treat Challenging CNS Cancers
Hitting Previously Undruggable Targets with Oral Therapies
Building Better Models of Human Diseases to Speed Drug Development
Preventing Opioids from Countering the Benefits of Cancer Immunotherapies
Better Living through Computational Chemistry
Outsmarting a Clever One
The Search for a New Approach to Male Contraception
Crafting a One-and-Done Epigenetic Editor to Tackle Hepatitis B
Fueling AI Drug Development with Patient Biology
The Search for Better Obesity Treatments
A Novel Approach to Treating Chronic Low Back Pain
A Biologic Designed to Treat Acute Exacerbations of Asthma and COPD
Turbocharging Drug Discovery with Health Data
Revolutionizing the Production of Biologics with Algae
Making Medicines for a World of People with Cancer
Harnessing Myeloid Cells to Attack Cancer
Drawing Lessons from the COVID Pandemic
A Bet that Myostatins Can Muscle Out Obesity
Making Whole-Eye Transplantation a Reality
Synbio Companies Come to Grips with the One “Omic” that Matters
Searching for Safer Pain Medications
Bridging the Translational Divide in Healthcare AI
Seeking Long-Term Pain Relief from a Drug-Free Injection
Engaging Hard-to-Target Receptors with Antibodies that Activate
An Insider’s View of the Patent Fights that Shaped the Biotech Industry
Restoring Balance to the Immune System in Allergic Diseases
Turning Natural Killers into Off-the-Shelf Therapies for Autoimmune Disease
Combining an Antibody and siRNA to Treat Hepatitis B
Looking at the Promise of GLP-1 Agonists Beyond Obesity
An Off-the-Shelf Cancer Vaccine Faces a Final Clinical Hurdle in NSCLC
A Nose for Attacking Brain Cancer
An Unnatural Approach to Undruggable Targets
Expanding the Drug Developer’s Chemical Universe
Take 100 Megabytes a Day and Call Me in the Morning
Extracting the Benefits of Psychedelics
A Magellan that Circumnavigates Active Binding Sites
A Very Meh-Ry Biotech Year and What’s Ahead in 2025
Using Light to Biomanufacture a Steak
Sit, Stay, and Heal: Bringing Precision Medicine to Dogs, then Humans
Targeting the Undruggable Proteome
Preventing a Deadly Disease by Detecting It Before It Becomes Cancer
Getting Tumors to Say “Eat Me”
Targeting the Dark Matter of the Genome to Treat Diseases
Using AI to Discover Small Molecule Alternatives to Biologics
A BET on a Novel Approach to Treat Autoimmune Conditions
Cell Therapies that Can Do a Solid for People with Cancer
Going to Extremes to Discover New Drugs
Targeting Senescent Cells to Treat Aging-Related Diseases
Bringing Cellular Diversity into Sharper Focus
Developing Cancer Therapies for When Damage Control Goes Awry
Delivering the Goods
Swimming in the New Oil
Does This Drug Represent “A Paradigm Shift for Small Molecule Drug Development?”
Exploring the Promise and Peril of CRISPR
Transforming Protein Engineering with Generative AI
Delivering Peptide Therapies Orally
Creating A Drug Delivery ARMMs Race
A Seek and Destroy Approach to Disease-Causing Proteins
Teaching Tolerance to Address Autoimmune Diseases
A Bet That the Next Blockbuster May Already Be Inside You
A Big Mac Attack to Fight Cancer
Getting Animated about Bioliteracy
Reshaping Clinical Trial Designs with Real-World Data
Using Generative AI to Produce Precise Gene Editors
Enabling the Nervous System to Repair Itself
Overcoming Barriers to Delivering Large Molecules to the Brain
Developing Complex Therapies to Tackle Complex Diseases
How Solving a Problem with Genetic Medicines May Solve Another with Infectious Diseases
Boosting the Power of Dendritic Cancer Vaccines
Overcoming Resistance in Cancer with Chemistry
Teaching an Old Drug a New Trick to Prevent Lyme Disease
A New Class of Cell Therapies to Target Solid Tumors
Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies
A Company Born from a Father Who Wore His Heart on His Sleeve
Using AI to Improve Burn Care
A Home for Biotech in the City that Never Sleeps
Biopharma R&D Growing Stronger
The Benefits of Having a Multitude of Cins
Making ADCs Smarter and Safer with a Simple Twist of Fate
Targeting a Natural Repair System to Restore Brain Health
Programing Cells in a Predictable and Scalable Way
Why DNA May Be the Data Storage Medium of the Future
Scouring Genetic Variation within Our Cells for Drug Targets
Correcting Gene Dysregulation to Treat Diseases
Using Technology to Regain Abilities after Spinal Cord Injury
Why Drug Developers Have a Growing Interest in Targeting Mitochondria
Beefing Up Computational Muscle to Understand Molecular Activity of Drug Candidates
Targeting a Multitude of CIN in Cancer Cells
The Year in Biotech and What’s Ahead in 2024
Transforming Healthcare with Data
Realizing the Promise of IL-2 Therapies with AI
Unlocking Real-World Data to Improve Outcomes
A Silicon Valley Entrepreneur Investing at the Intersection of Tech and Biotech
A Company Betting Its Physics-Based AI Will Fuel a Quantum Leap in Drug Discovery
Detecting Alzheimer’s Disease Early through a Blood Test
Addressing Supply-Chain Challenges Underlying Drug Shortages with Synthetic Biology
Building Better and More Affordable Vaccines
Overcoming Resistance to Targeted Therapies
Using Tumor Gene Therapy to Overcome Barriers to Immunotherapies
Using AI to Generate Mini-Protein Therapeutics
Inhibiting Cell Death to Preserve Vision in Retinal Diseases
Leveraging Generative AI to Design Therapeutic Antibodies
Managing Pain without Addiction
Using AI to Match Cancer Patients to their Best Treatment Options
A Venture Capitalist’s View of the Current Biotech Landscape
Realizing the Therapeutic Potential of Cytokines by Making them Context Dependent
Targeting Cancer and Autoimmune Conditions with Donor-Derived EBV T Cells
Reprogramming the Tumor Microenviroment to Activate an Immune Response
Making Safer and More Effective Vaccines with Targeted mRNA
Addressing a Global Need with RNA Vaccines and Immunotherapies
Targeting Bacteria in Chronic Diseases
Targeting Solid Tumors with Off-The-Shelf CAR T Therapies
Reimagining the Development of Immunotherapies with a Venture Studio
Repairing the Body with Advanced Cell Therapies
Achieving Precision with AI Pathology
Inducing Potent and Durable T Cell Responses to Fight Disease
Developing Immunotherapies that Target the Drivers of Cancer
Using Phase 0 Trials to Bring Precision Medicine to Treating Brain Tumors
Restoring Feeling and Function to Damaged Nerves
Enlisting Vaccines in the Fight Against Chronic Diseases
Extending the Reach of Protein Degradation Therapies
Growing the Bioeconomy
Developing Targeted Therapies to Address Resistance in Cancer
It Takes a Village
Bringing Stick-to-itiveness to Regenerative Medicine
A Biopharma Downturn or Return to Trend
Treating Aging-Related Disease by Targeting Molecular Drivers of Aging
Engineering Better Cell Therapies for Cancers
Targeting a Regulator of Inflammation to Treat Alzheimer’s Disease
Enabling Regenerative Therapies without Immunosuppression
Making Vaccine and Biotherapeutic Production Fast and Affordable
Forcing Cancers to Reveal Themselves
Making Clinical Trials Diverse and Accessible
Mining Bugs for Drugs
A Company That Bets Its Therapies Will Click with Patients
A Company Where It takes Guts and Brains to Develop Drugs
Changing Outcomes with Data
Treating Psychiatric Conditions with Tripless Psychedelics
How AI Is Finding Its Way into Unexpected Places in Biopharma Companies
Searching the Dark Matter of the Proteome to Develop New Therapies
The Year in Biotech and What’s Ahead in 2023
Targeting a Novel Checkpoint to Treat Cancer and Autoimmune Conditions
The Growing Need for Biosecurity Vigilance
Enlisting Next-Generation Cytokine Immunotherapies in the Fight Against Cancer
Engineering Safer and More Effective Cell Therapies
Changing Drug Discovery for Neuropsychiatric Disorders with Phenotypic Screens
Using Virtual Reality-Guided Mindfulness to Treat Chronic Pain in Cancer Patients
Activating the Adaptive and Innate Immune Systems to Fight Cancer
A Longevity Fund Focused on Young Companies
Learning from “Elite” Responders to Develop Better Immunotherapies
Bringing Precision Medicine to the Treatment of Obesity
Expanding the Promise of RNA Therapies
Triggering a Systemic Immune Response Against Cancer
Targeting RNA Dysregulation in Cancer
Building a Pipeline of Next-Generation Kinase Inhibitors
Rethinking How Cell and Gene Therapies Are Made to Improve Accessibility
Developing Next-Generation Radiopharmaceuticals
Why Great Science and Data Aren’t Enough
Targeting Sugars that Let Cancers Evade the Immune System
Engineering Stem Cells to Withstand Targeted Therapies
Targeting a Convergence of Signaling Pathways that Drive the Growth and Spread of Cancer
Moving from Preservation to Restoration with Off-the-Shelf Cell Therapies
Using Gene Therapies to Treat Chronic, Inflammatory Conditions
Unlocking the Full Potential of Antibody Therapies
Combatting Superbugs and Emerging Viruses
How a Plant-Derived Gel Halts Bleeding in Seconds
Exploiting a Vulnerability in Cancers
Democratizing AI
A Rapid Onset Nasal Spray to Treat Mental Health Conditions
A Regenerative Medicine Company Puts Its Off-the-Shelf Vessel Replacements to the Test in Ukraine
Battling Resistance in Tumors with “Pan-Variant” Kinase Inhibitors
Treating Disease by Editing Genes in the Microbiome
Embracing the Promise of Natural Killer Cells in the Fight Against Cancer
Addressing Neurodegenerative Disease by Suppressing a Hyper Immune Response
Bringing Precision Medicine to Psychiatry
Attacking Neurodegenerative Diseases with Protein Degraders
Restoring Immune Activity While Suppressing Cancer Proliferation
A New Model for Preventing Life-Threatening Blood Clots
The Race to Live Forever
A Model for Moving from Breakthrough to Blockbuster
Building the Next-Generation of Cell and Gene Therapies
Building Small Molecule Drugs that Are Superior to Biologics
A New Class of Cancer Therapies Targets Solid Tumors with a Dual Action
A Pursuit of Off-The-Shelf CAR-T Therapies
Mapping the Human Proteome
Gene Therapy Provides Hope to Hemophilia B Patients
Making Data-Driven Medicine a Reality
A Neuroscientist Turned Venture Investor Discusses TechBio Investing
A Nonprofit Seeks to Make Cell and Gene Therapies Affordable Worldwide
Disposing Toxic Proteins to Treat Neurodegenerative Diseases
Repurposing a Drug for Parasitic Infections as a Targeted GI Therapy
Targeting Chronic, Low-Grade Inflammation to Address Diseases of Aging
The Year in Biotech and What’s Ahead in 2022
Restoring the Guardian of the Genome to Fight Tumors
Advancing a Cell Therapy with the Potential to Cure HIV
Harnessing More Efficient Organisms to Reshore BioManufacutring
Using Digital Health Technology to Bring the Trial to the Patient
Using the Body’s Housecleaning Mechanism to Target Undruggable Proteins
Advocating for the Extension of Healthy Life
Using Donated Living Skin as an Alternative to Animal Testing
A Platform to Scale the Production of Personalized Cell Therapies
Developing Small Molecule Therapies to Target Proteins Only Biologics Have Been Able to Hit
Targeting Solid Tumors with Oncolytic Viruses
Reinventing the Discovery and Cell Line Development of Biotherapeutics
Engineering Off-the-Shelf Cell Therapies to Target Solid Tumors
Democratizing Drug Discovery
Scaling Genetic Counseling Services with AI
Programming Cell Therapies to Overcome Solid Tumor Defense Systems
Using Liquid Biopsies to Diagnose Infectious Diseases
Striking Hepatitis B at Its Core
Modulating Serotonin with Psychedelics to Treat Neuropsychiatric Conditions
A Procedural Therapy Seeks to Address Type 2 Diabetes at Its Root Cause
Building a Better Path to Neurotherapeutics
Taking a Portfolio Approach to Immuno-Oncology
Engineering Life to Reach New Worlds
Targeting Cancer Drug Side Effects at Their Source
Mapping the Universe of Human Proteins
Fighting Disease by Modulating the Translation of Proteins
Fixing Biopharma’s R&D Productivity by Taking a Cue from the Tech Industry
An Affordable and Widely Available Drug Offers Global Hope against COVID
A Gene Therapy to Program the Body to Produce a Treatment for Osteoarthritis
A Test for Data-Driven Drug Development
Bridging the Gulf Between the Promise and Reality of Precision Health
Using Synthetic Biology to Craft One-Time, Programmable mRNA Therapeutics
Using a Digital Cognitive Behavior Therapy to Treat Diabetes and Heart Disease
Disrupting Pain Signals with Precision
A Diagnostics Company Moves to Developing Precision Cancer Therapies
Characterizing the Immunome at Scale
Delivering Oxygen to Tissue in Need
Using Gene Therapy to Create a Drug Biofactory within a Patient
Finding New Uses for TNF Inhibitors
Using AI to Map the Undiscovered World of Bioactive Compounds in Plants
Improving the Delivery of Drugs through Thin Film Freezing
Using CRISPR to Target RNA Instead of DNA
An Antisense Pioneer Brings Custom Treatments to Patients with Ultra-Rare Conditions
Managing Neurodegenerative Diseases with Better Data to Improve Outcomes
A Small Molecule Cancer Drug That Promotes an Adaptive Immune Response
Sloan-Kettering Spin-Out Harnesses AI to Diagnose Cancer
Bringing Innovation to Cell and Gene Therapy Manufacturing
Tapping Psychedelics for their Anti-Inflammatory Powers
Advancing Cell Therapies Beyond Cancer
How the Pandemic Transformed a Small Diagnostics Company
Eliminating Security, Privacy, and Regulatory Burdens with Synthetic Data
Using Computational Discovery to Build Better Immunotherapies
The Year in Biotech and What’s Ahead in 2021
Bringing Precision Cancer Care to Dogs
As COVID-19 Vaccines Ship, One Company Brings Innovation to the Vials
Advancing an Antibody to Prevent and Treat Cytokine Storms in COVID-19
Using AI Created Digital Twins to Accelerate Clinical Trials
Modulating RNA to Quell Disease
A Quest to Extend Life through Early Disease Detection
Modulating a Gatekeeper of Cellular Metabolism to Treat a Range of Diseases
Finding the Best Cell for the Job
Transforming Clinical Trials with Digital Technology
Designing Immunotherapies that Can Overcome Recurrence and Resistance
Extending Precision Medicine Beyond Cancer
Growing Biologics
An Experimental COVID-19 Vaccine Begins Human Clinical Trials
Speeding the Delivery of CAR-T Therapies While Cutting the Cost
Transforming Infused Biologics into Injectables
A Novel Approach to NASH That May Have Benefits for COVID 19 As Well
Will a Focus on Protein Dysregulation Help Prothena Break from the Fold
After FDA Set Back, AI Driven Drug Company Advances with New CEO
A Gamified Therapy System Helps People with Brain Injury Recover
Genentech Drug Offers Oral, at-Home Option for SMA Patients
Enabling Precision Medicine through Proteomics
Battling Drug-Resistant Fungal Infections
Making Colorectal Cancer Screening Less of a Pain in the Ass
Targeting Diseases of Aging at a Cellular Level
Cracking the Immune System with AI
Using AI to Improve Drug Companies’ Regulatory Performance
Delivering Biologics Orally
Turning Proteins into Device Coatings that Provide Therapeutic Benefits
Testing if an Approved Antiviral May Prevent COVID-19 Outbreaks
Using AI to Crack COVID-19
Why An Experimental Therapy for Inflammatory Disorders Could Help the Fight Against COVID-19
Modernizing Phage Therapy to Kill Multidrug-Resistant Bacteria
A Rare Disease Drug Hunter Turns His Attention to COVID-19
What It Will Take to Move Beyond the Pandemic
Reading, Writing, and Erasing the Way to Epigenetic Cancer Therapies
Better Immunotherapies Through Chemistry
Bringing the Trial to the Patient
Controlling the Activity of Cell and Gene Therapies with Precision
Why Soon-Shiong Thinks His Triangle Offense for Cancer Can Be Applied to COVID-19
COVID-19, Vaccine Development, and Global Health Lessons from Ebola
Improving Cancer Outcomes with Early Diagnosis
Making A Social Contract That’s Enforceable
Treating Alzheimer’s Disease as an Autoimmune Condition
Fishing for New Drugs
Thoughts on the State of the Antimicrobial Arsenal
A MedTech Company That Thinks Like a Biopharma
Tapping the Potential of Psychedelics to Treat Psychiatric Conditions
Quantifying Neurodegeneration with Precision
Orasis Developing Eye Drops as Alternative to Reading Glasses
Reversing Disease Signals
Turning Cold Tumors Hot
Stabilizing Neuronal Connections to Treat Cognitive Impairment in Alzheimer’s
Our Annual Biotech Review/Preview with STAT’s Adam Feuerstein
An Effort to Eradicate Preventable Blindness
Seeking Success Where Others Have Failed
A New Antibiotic with a Unique Mechanism of Action Hits the Market
Improving Health with Better Data
An Effort to Bioprint a Transplantable Human Heart
How Doctors Are Cracking Difficult Cases with a Social Network
Cala Health Hopes to Win Over Payers and Providers with Its Bioelectric Medicine
Shaping the Emerging Bioeconomy
A Belief that Early Interventions Will Be the Key to Treating Alzheimer’s Disease
Transforming the Study of Microbes with High-Throughput Technology
Using RNA Diagnostics to Predict Patient Response to Immunotherapies
How a Clever Business Model May Accelerate the Use of Companion Diagnostics
Building Cell Therapies with Switches to Modulate Their Activity
Using Synthetic Biology to Build Intelligence into Cell and Gene Therapies
A Therapeutic Approach Built on Protein Degradation
Harnessing AI to Improve Sales and Marketing Decision-Making
A Doctor’s Quest to Cure His Own Rare Disease
Athersys Advances Off-the-Shelf Stem Cell Therapy for Stroke
Enlisting the Innate Immune System to Fight Cancer and other Diseases
Using AI to Improve Clinical Development
Addressing the Challenge of Making Antibody-Drug Conjugates
Targeting Regulators of Genes to Treat Cancer
Harnessing the Immune System to Diagnose and Treat Cancer
Using Synthetic Biology to Produce Cannabinoids
EpicentRx Hopes Rocket-Fuel-Derived Drug Will Propel It
Using Fruit Flies to Personalize Cancer Therapies
Bridging the Gap Between Data and Knowledge with AI
How Virtual Reality May Change the Way Researchers Discover and Develop Drugs
Addressing the Challenges of Drug Development with a New Market
Addressing the Challenge of Producing Stem Cell Therapies with Consistency at Scale
Ensuring a Placebo Response Doesn’t Derail a Clinical Trial
Using AI to Find New Uses for Validated Drugs
Using Digital Health to Change Our Understanding of What Drives Disease
Cidara Advances Antiviral Conjugate to Treat and Prevent Flu
Building a Drug Empire on Undervalued Assets
Bringing Precision Medicine to Autoimmune Disease
Fighting Drug-Resistant Fungal Infections
Accelerating Early-Stage Biotechs
Agenus Advances Broad Immuno-Oncology Pipeline
Targeting the Right Proteins to Treat Neurological Diseases
A Treat Locally, Act Globally Strategy for Treating Cancer
Squeezing New Possibilities into Cell Therapies
Industry Calls for New Incentives to Spur Development of New Antibiotics
Company Seeks to Prove Marine-Derived Alzheimer’s Drug Is No Fish Story
Targeting the Plasma Proteome to Address Diseases of Aging
Teaching Scientists to Be Effective Communicators
Designing Small-Molecule, Immuno-Oncology Drugs That Act Like Biologics
Biohacking for the Masses
A Hearts and Minds Strategy for Cardiovascular Disease
A Drug Hunter Finds Greater Freedom at a Nonprofit Institute
Attacking IBD Through a Novel Pathway
Writing the Future of Drug Research with Bioink
An Effort to Develop Safer and More Effective Immunotherapies
The Year in Biotech and What to Watch in 2019
Why One Investor Is Betting on Platform Technologies to Change the World
Price Transparency and a Healthcare Policy Analyst’s Brush with the Healthcare System
How a Leading Health Sciences University is Working to Address Homelessness
Gecko Looks to Broad Applications in Tissue Reconstruction
The Search for Mediators of Aging
Using Drug Delivery Technology to Improve ADHD Therapies
How One Company Is Targeting a Growing Opportunity in Women’s Reproductive Health
Why an HIV Drug in Development Could Change How Cancer Is Treated
How the Rise of the Patient-Consumer Is Changing Clinical Trials
Bringing Real-World Monitoring to Autoimmune Disease
Using Real-World Evidence to Improve Drug Development
Enlisting Immunotherapies in the Fight Against Infectious Diseases
Tackling the Problem of Resistance in Chemotherapy
Engineering Bacteria for Therapeutic Benefit
The Promise of Organ-on-a-Chip Technology to Improve Drug Development
Harnessing AI to Fight Diseases of Aging
Transforming Clinical Trials with Digital Health Technologies
Why Foresite Capital is Betting Big on the Convergence of AI and Biotech
Why Public Health Systems Need to Be Better Prepared for Extreme Weather Events
Predicting the Unpredictable Off-Target Activities of Drugs
Why Clinics Providing Stem Cell Therapies not Approved by the FDA Are Creating Growing Concern
Making Biomedical Discoveries Sooner
Reinventing Drug Discovery with AI
Carrying Therapeutic Payloads Across the Blood-Brain Barrier
Harnessing Bacteria to Improve Skin Health
How One Accelerator Tries to Give Early-Stage Drug Developers an Edge
Making Synthetic Biology a Commercial Reality
Why Behavioral Economics May Turn Irrational Patients Rational
Pushing the Frontiers of Longevity
Is Hearing Loss a Necessary Price for Children to Pay for Life-Saving Chemotherapies
Why Diagnostics May Be Critical to Reshaping Alzheimer’s Drug Development
Why the Diversity of Genomic Data Matters
Why Biomarkers May Be the Key to Immuno-Oncology Success
Seeing Virtue in Patients
When Science Becomes a Cause
The Pursuit of Healthier, Safer, and More Humane Meat
A Hidden Killer and Why Patients Face Barriers to Accessing Promising New Drugs for It
Targeting the Regulators of Genes to Treat Disease
Price-Fixing Case Against Generic Drugmakers Widens
Outcomes Erode for Newborns and Mothers in Rural America as Hospitals Lose Obstectric Services
Why Drug Companies May Soon Become Health Technology Companies
After Facing Death, Former HR Director Helps Others Get a New Perspective on Life
Putting Physics to Work in the Fight Against Cancer
Why Aging Might Best Be Thought of as a Disease
Looking for a Better Alternative to Chemotherapy for AL Amyloidosis
A University Spin-Out that Incubates University Spin Outs
Understanding the Challenges and Opportunities of Patient-Centric Outcomes
How CellMax Hopes to Change the Diagnosis Cancer with Inexpensive Liquid Biopsy
How Surveillance and Data Are Bringing Precision to the Treatment of Prostate Cancer
Why Life Sciences M&A Should Heat up This Year
The Outlook for Biotech in 2018
The Year in Biotech and What to Watch in 2018
The Year in Immuno-Oncology and What to Watch in 2018
What the Approval of the First Digital Pill Means for the Future of Healthcare
Why Public Health Systems Need to Be Better Prepared for Extreme Weather Events
Former CDC Director Takes on World’s Leading Cause of Death
How a Public-Private Consortium Is Revolutionizing Cancer Drug Discovery
How Faulty Thinking Can Derail Life Sciences M&A Deals
Targeting Drug-Resistant Bacteria with an Ancient Enemy
A Bioelectronic Approach to Treating Autoimmune Diseases
Harnessing Patient Data to Improve Drug Development Efficiency
How Colorifix Is Trying to Turn the Textile Industry Green
Targeting Patients as Sick as Dogs
A Strategic Investor’s View of the Biotech Investment Landscape
Bringing Gender Diversity into Biotech Boardrooms
Why the FDA May Need to Rethink Its Approach to Gene and Cell Therapy
VBL Targets Brain and other Cancers with Novel Immunotherapy
What Will It Take to Transform Healthcare to a System Focused on Prediction and Prevention
Can a Direct Pitch to Patients Drive a Home Run for Obesity Drug
Why Companies Across Industries Need to Develop a Bio Strategy
Economist Argues Maximizing Shareholder Value Hurts Drug Innovation
Partnership Drives Development of Antibiotic to Combat Resistant Gonorrhea
CIRM-Funded Pipeline of Regenerative Therapies Advances
Technology Allows Drugmakers to Tag and Authenticate Individual Pills
Harnessing Mosquitoes to Fight the Spread of Infectious Disease
Biotech Industry Moves Towards a Patent Cliff
PvP Takes a Unique Approach to Treating an Autoimmune Disease
Uncertainty Hangs over the Biotech Sector
What Others Can Learn from COI’s Approach to Cost-Efficient Drug Development
Dyadic Seek to Bring Disruptive Technology to Biomanufacturing
Enlisting the Immune System in the Battle Against Alzheimer’s
Overcoming the Delivery Challenges of Gene Therapy
Brexit Sparks Battle to House the EMA
New Safety Concerns Identified After FDA Approval of One in Three Drugs
Why Climate Change Is a Public Health Concern
Reflections on the Progress and Promise of Personalzied Medicines
Curing Cancer with Math
How Healthcare Consumer Find and Use Price Information
Why Infectious Disease Represents a National Security Threat
Recent Mumps Outbreaks Raise Question If New Vaccine Is Needed
Proposed Legislation Would Weaken Genetic Privacy Protections
How Biomarkers Can Alter the View of and Approach to Alzheimer’s Disease
The Fight for Personalized Medicine Wages on Many Fronts
Big Pharma and the Growth and Outlook for Orphan Drugs
What the Recent Patent Ruling Means for the Future of Gene-Editing Technology
Weighing What Limits Should Be Put on Gene Editing
Enlisting the Immune System in the War on Cancer
Why Scientists Must Also Be Advocates
Sernova Eyes Range of Disease for Implantable Cell Technology
Stratus Wants to Demonstrate Its Telehealth Fluency
Regeneron Embraces Genetics as Fundamental to Drug Development
Despite FDA Setback, KemPharm Advancing Prodrug Pipeline
Using digital technologies to improve diagnosis and treatment of mental health patients
Biotech in 2016 and the Year Ahead with TheStreet’s Adam Feuerstein
Harnessing Gut Bacteria to Treat Disease
A Look at What’s Ahead for Biopharma in 2017
AMA Wants Docs to Have Seat at mHealth Table
Testing of New HIV Vaccine Carries Hopes of a Breakthrough
Centrexion Takes Aim at Pain with Growing Portfolio of Non-Opioid Therapeutics
Bringing Women into Biotech Boardrooms
Novartis Deal Validates Perlara’s Approach to Rare Disease Drug Discovery
Harvesting the Aquatic Microbiome for New Drugs
How TwoXAR Is Using Big Data to Accelerate Drug Discovery
Developer of innovative catheter for cancer drugs turns to crowdfunding
Harnessing Real World Samples and Data to Speed Biomedical Research
A Rich Pipeline Expected to Drive Industry’s Growth
Harnessing Biology to Transform the Economy
How a Predictive Diagnostic Can Reduce Preterm Births
Building Better Drugs for Psychiatric Disorders by Targeting the Causes
The Role of PBMs in the Controversy over Drug Pricing
Why a Rare Genetic Disease May Shed Light on Normal Aging
Battling Zika and Other Diseases Like It
Chronicling a Trailblazer of the Genomics Age
Great Progress, but Concerns Persist About Cancer Care in America
Improving Healthcare by Addressing the Most Challenging Patients
The Case for Chasing Unpopular Indications
Improving Drug Development through Better Use of Biomarkers
Measuring the Value of Incubators and Accelerators
Enlisting New and Old Tools to Combat Antibiotic Resistance
Advancing Cancer Care with New Diagnostic Tools
A Biotech Reinvents Itself and How to Price Drugs
Using Technology to Modernize Preclinical Development
Can the Biotech Industry Stay on Track through Innovative Pricing
Wall Street Turns Its Eyes to ASCO
Understanding the Disease It Never Was on House
Why the State of Innovation Is Encouraging
Can Market Forces Fix Drug Pricing
Digital Health Device Seeks to Push Beyond Cannabis to Test Food, Air, and Water
Why the Cancer Moonshot Offers a Chance to Rethink Funding Priorities
Medtronic Advances Toward an Artificial Pancreas
Using Real-Time Data to Detect HIV Outbreaks
Why Pharma Needs to Forge New Drug Pricing Models
Gensight Targets Gene Therapy on Diseases that Blind
A Vial Problem: How We Waste $3 Billion of Cancer Drugs a Year
The Havoc-Wreaking Zombies Lurking in Life Sciences Boardrooms
New FDA Chief Faces Challenges
Seeking a Best-in-Class Antibody at Bargain Basement Prices
Pharma Bro, Price Controls, and the Quest to Balance Innovation with Affordability
California’s Stem Cell Agency Plots Its Future
ViaCyte Pursues ”Functional Cure” for Type 1 Diabetes
Building a Better Pain Pill
Project GENIE Hopes to Make Precision Medicine a Reality
FDA Wants Industry to Guard Against Cybersecurity Risks of Medical Devices
Pharma’s Leadership Vacuum and Its Price to the Industry
Permanent R&D Tax Credit a Boost to Life Sciences
Biotech in 2015 and the Year Ahead with TheStreet’s Adam Feuerstein
Trends Shaping the New Health Economy in 2016
Declining R&D Productivity Continues to Plague Big Pharma
Searching for Solutions to Rising Specialty Drug Prices
Biohackers Seek a Faster, Cheaper Path to Insulin
A Scorecard to Improve Drugmakers’ Transparency
Forget the Chemistry Set, Mom, I Want a Bioreactor
Ensuring Biological Tools Benefit the Environment
New SEC Rules Open Crowdfunding to the Masses
Harnessing Biology to Address Global Challenges
Immunotherapies ETF Lets Biotech Investors Bet on Emerging Sector
Biotech Investors Turn Their Eyes to Policy Matters
Why the MedTech Industry Should Worry About Future Innovation
Rare Disease Drug Developer Shows Speed of Business Model
Ensuring Value-Based Care Addresses What Matters to Patients
California, Aid-in-Dying, and What We’ve Learned from Oregon
FDA Guidance on Names for Biologics and Biosimilars and its Implications
Understanding the Cost and Value of Cancer Therapies
Jimmy Carter’s Final Wish: Eradicating Guinea Worm
The Quest for a Pink Viagra
Free Speech Ruling May Force FDA to Rethink Off-Label Marketing
Drugmakers Often Late to Report Serious Side Effects
When Hospital Cause, Rather than Cure, Deadly Infections
Rethinking the Value and Price of Drugs
Harnessing Stem Cells to Test Drug Safety
CrowdMed Enlists the Wisdom of Crowds to Solve Medical Mysteries
Biotech’s Record Performance and Looming Threats
What a Decade of Investment Tells Us about the Health of Biotech
What Activist Investors Can Teach Biotech Companies
ALS Fight Carries Muller from Patient to Biotech CEO
Examining the State of Sleep
TheStreet’s Adam Feuerstein Previews ASCO 2015
Home-Brew Morphine, Dual Use Technology, and the Biologist’s Repsonsibilities
Reinventing Tech Transfer
Thinking Narrowly About Antibiotics
Promise Shown in Different Approach to Alzheimer’s
Innovative Drugs Drive Big Increase in U.S. Spending
Ensuring Digital Health Technologies Benefit Older People
How the Sugar Industry Influenced Research to Protect Its Interests
Examining The White House’s Plan to Combat Drug-Resistant Bacteria
Weighing Adverse Events to Get at a Drug’s Real Costs
How One Company Is Reinventing Drug Development
Why Patent Trolling Threatens Biopharma
Shifting Venture Investment Raises Concerns
Will Policy Triumph Over Politics in 21st Century Cures Act
Democratizing the World of Healthcare Analytics
Will Funding for Obama’s Precision Medicine Initiative Match Its Ambition
Should Investors Temper Their Enthusiasm for CAR-T Therapies
What to Do About the United States’ Declining Investment in R&D
Why Big Pharma Hasn’t Been Able to Fix Its Revenue Gap with M&A
Remembering Industry Pioneer Ron Cape
Moving from Chronic Therapies to Cures
What’s in Store for the Biotech Industry in 2015
A Look at the Year That Was in Biotech
Why Privacy Concerns May Limit Big Data’s Payoff
Calculating the Cost of Drug Development and What it Means
How New Funding Models Are Accelerating Drug Development
Telemedicine Grows, but Reimbursement Remains an Obstacle
The Power of IBM’s Watson Is Coming to an App Near You
Brittany Maynard and the Debate over the Right to Die
What’s Driving the Booming Market for Orphan Drugs
Why Interoperability Is Much More than a Technology Problem
The Lean Startup Takes Hold in the Life Sciences
Enlisting Monoclonal Antibodies to Combat Bacterial Resistance
The Forces Bringing Disruptive Change to Healthcare
How One Foundation is Getting the Biggest Bang for Its R&D Bucks
International Collaboration Seeks to Drive Breakthroughs in Progressive MS
Will Increased FDA Regulation of Diagnostics Speed or Slow Development of Personalized Medicine
Using Human Biology to Improve R&D
Reengineering Drug Discovery and Development
The Year in Biotech So Far and What’s Ahead
Epirus Sees Opportunities for Biosimilars Outside U.S.